Skip to Content

Generic Tagamet Availability

Tagamet is a brand name of cimetidine, approved by the FDA in the following formulation(s):

TAGAMET (cimetidine - tablet;oral)

  • Manufacturer: GLAXOSMITHKLINE
    Approved Prior to Jan 1, 1982
    Strength(s): 200MG, 300MG
  • Manufacturer: GLAXOSMITHKLINE
    Approval date: December 14, 1983
    Strength(s): 400MG
  • Manufacturer: GLAXOSMITHKLINE
    Approval date: April 30, 1986
    Strength(s): 800MG

TAGAMET (cimetidine hydrochloride - injectable;injection)

  • Manufacturer: GLAXOSMITHKLINE
    Approved Prior to Jan 1, 1982
    Strength(s): EQ 300MG BASE/2ML

TAGAMET (cimetidine hydrochloride - solution;oral)

  • Manufacturer: GLAXOSMITHKLINE
    Approved Prior to Jan 1, 1982
    Strength(s): EQ 300MG BASE/5ML

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tagamet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide